PHARMA-BIO SERV, INC. — Operating Income by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/0fde85cd-9c14-4504-ad90-f12842d7f4a5/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-637.7k | 2024-11-01 – 2025-10-31 | evidence 0001654954-26-000710 |
| FY 2024 | $-1.3M | 2023-11-01 – 2024-10-31 | evidence 0001654954-25-000915 |
| FY 2023 | $1.1M | 2022-11-01 – 2023-10-31 | evidence 0001654954-24-000996 |
| FY 2022 | $1.2M | 2021-11-01 – 2022-10-31 | evidence 0001654954-23-001018 |
| FY 2021 | $-3.9M | 2020-11-01 – 2021-10-31 | evidence 0001654954-22-001532 |
| FY 2020 | $2.2M | 2019-11-01 – 2020-10-31 | evidence 0001654954-21-000973 |
| FY 2019 | $1.7M | 2018-11-01 – 2019-10-31 | evidence 0001654954-21-000973 |
| FY 2018 | $-1.3M | 2017-11-01 – 2018-10-31 | evidence 0001654954-19-000854 |
| FY 2017 | $-777.8k | 2016-11-01 – 2017-10-31 | evidence 0001654954-19-000854 |
| FY 2016 | $-91.8k | 2015-11-01 – 2016-10-31 | evidence 0001654954-17-000601 |
| FY 2015 | $1.8M | 2014-11-01 – 2015-10-31 | evidence 0001354488-16-006025 |
| FY 2014 | $2.9M | 2013-11-01 – 2014-10-31 | evidence 0001354488-15-000359 |
| FY 2013 | $6.1M | 2012-11-01 – 2013-10-31 | evidence 0001354488-14-000379 |
| FY 2012 | $5.7M | 2011-11-01 – 2012-10-31 | evidence 0001354488-13-000352 |
| FY 2011 | $3.5M | 2010-11-01 – 2011-10-31 | evidence 0001354488-12-000360 |
| FY 2010 | $609.9k | 2009-11-01 – 2010-10-31 | evidence 0001354488-12-000360 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).